LASSBio-2052

CAT: 0804-HY-161617Size: 1 EachDry Ice: NoHazardous: No
CAT#:0804-HY-161617Size:1 Each
Selected
PRICE
AVAILABILITY: InStock
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Product image 1
1 / 1
Description
LASSBio-2052 is a derivative of N-acylhydrazone with antitumor activity against hepatocellular carcinoma (HCC) . LASSBio-2052 inhibits HCC cells HepG2 and Hep3B, with IC50 of 18 and 41 μM. LASSBio-2052 arrests the cell cycle at G2/M phase, through downregulation of FOXM1. LASSBio-2052 induces apoptosis in HCC cells[1].
CAS Number
[2549160-15-6]
UNSPSC
12352005
Target
Apoptosis; DNA/RNA Synthesis
Type
Reference compound
Related Pathways
Apoptosis; Cell Cycle/DNA Damage
Applications
Cancer-programmed cell death
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/lassbio-2052.html
Solubility
10 mM in DMSO
Smiles
O=C(N/N=C/C1=CC=C(C(F)(F)F)C=C1)C2=CC=CC=C2NCC3=CC=C(OC)C(O)=C3
Molecular Formula
C23H20F3N3O3
Molecular Weight
443.42
References & Citations
[1]Andrade AAR, et al., Antiproliferative Activity of N-Acylhydrazone Derivative on Hepatocellular Carcinoma Cells Involves Transcriptional Regulation of Genes Required for G2/M Transition. Biomedicines. 2024 Apr 18;12 (4) :892.
Shipping Conditions
Room temperature
Scientific Category
Reference compound1
Clinical Information
No Development Reported

Related Products

CatalogName
HY-157956LASSBio-873
HY-120941LASSBio-1359
HY-170963LASSBio-1985
HY-131986-01LASSBio-1135
HY-131340LASSBio-1632
HY-161854LASSBio-1911
HY-R00417-01Hsa-miR-2052 mimic
HY-R00417A-01Hsa-miR-2052 agomir
HY-RI00417-01Hsa-miR-2052 inhibitor
HY-RI00417A-01Hsa-miR-2052 antagomir

Alternative Products

CatalogName
T86800-01LASSBio-2052
T61794-01LASSBio-1632
T24389-01LASSBio-1366
MBS3611897-01LASSBio-1135
T86801-01LASSBio-873
T24388-01LASSBio-1359
555260MLS-2052
T89313-01LASSBio-1911
T205058-01LASSBio-1985
MBS5782151LASSBio-881

Popular Products